Pfizer (PFE)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
At a market value of $154.9B, Pfizer's free cash flow of $9.1B (fiscal 2025) would need to grow about 3% a year for the stock to be worth today's price. That is faster than the company has grown its free cash flow over the last 9 years.
Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Pfizer's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.
Fundamental grade
Five factors scored 1 to 9 from PFE's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Pfizer's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $73.6B | $91.8B | $50.9B | $63.6B | $62.6B |
| Net income | $22.0B | $31.4B | $2.1B | $8.0B | $7.8B |
| Free cash flow | $29.9B | $26.0B | $4.8B | $9.8B | $9.1B |
| EPS (diluted) | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 |
| Operating margin | — | — | — | — | — |
Where the revenue comes from
Revenue by segments, fiscal 2023.
Superinvestors who own PFE
From each investor's latest 13F filing (what a 13F shows). 14 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Added | $445M | 0.16% | Q2 2026 |
| Charles Brandes Brandes Investment Partners, LP |
Trimmed | $184M | 1.3% | Q2 2026 |
| Michael Burry Scion Asset Management |
New position | $153M | 11.1% | Q3 2025 |
| Richard Pzena Pzena Investment Management |
Added | $143M | 0.42% | Q2 2026 |
| Ric Dillon Diamond Hill Capital Management |
Trimmed | $101M | 0.81% | Q2 2026 |
| Prem Watsa Fairfax Financial Holdings |
Added | $25M | 0.95% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | $22M | 0.05% | Q2 2026 |
| Mario Gabelli GAMCO Investors |
Trimmed | $14M | 0.12% | Q2 2026 |
| Thomas Kahn Kahn Brothers Group |
Trimmed | $11M | 1.8% | Q2 2026 |
| Bruce Berkowitz Fairholme Capital Management |
New position | $6M | 0.37% | Q2 2026 |
| Mark Boyar Boyar Asset Management |
Trimmed | $2M | 1.3% | Q2 2026 |
| Dodge & Cox Dodge & Cox |
Trimmed | $2M | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by Pfizer's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Feb 10, 2026 | Gilbert Ray Cisneros, Jr. |
0 | $27.61 | — |
| Feb 10, 2026 | Gilbert Ray Cisneros, Jr. |
0 | $27.61 | — |
| Nov 18, 2025 | Gilbert Ray Cisneros, Jr. |
0 | $25.45 | — |
| Nov 18, 2025 | Gilbert Ray Cisneros, Jr. |
0 | $25.45 | — |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when PFE trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
What growth does Pfizer's stock price imply?
At a market value of $154.9B, Pfizer would need its free cash flow to grow about 3% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew -5% a year.
Are Pfizer insiders buying the stock?
4 open-market insider purchases of PFE in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Pfizer?
14 of the superinvestors Investingly tracks hold PFE in their latest 13F, including Cliff Asness, Charles Brandes, Michael Burry.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.